Siberian State Medical University, Tomsk, Russian Federation
*Corresponding author: Kristina I. Yankovich, 1/8, Gerasimenko str., apt. #33, 634062, Tomsk, Russian Federation. Tel: 7-923-4253660.E-mail: email@example.com
The development of lung cancer is a complex and multistep process in which the functioning of many genes and the regulating mechanisms of the cell cycle, growth, cell differentiation, apoptosis, signals transduction from the cell surface to the nucleus, and DNA repair is structurally and functionally disrupted. Currently, specific attention has been paid to studies on the allelic polymorphism of oncogenes and oncosuppressors, which are the cell cycle regulators. We evaluated the frequency distribution of the alleles and genotypes of three polymorphisms: Bcl-2 (-938C>A), Bax (-248G>A), and p27 (-326T>G). Genomic DNA was obtained from 93 patients with lung cancer and 230 healthy controls. DNA samples were genotyped on the polymorphism of three genes. The study was performed using the PCR/RFLP analysis. The frequency of the minor genotypes of Bcl-2 (-938C>A) and Bax (-248G>A) polymorphisms in lung cancer patients was higher than that observed in the control group of healthy individuals. It was noted that risking relevance to the origin and development of lung cancer has a carrier functionally defective variants of cell cycle-regulated genes Bcl-2 (-938C>A) and Bax (-248G>A). The results of our study can be utilized to identify the groups at high risk of developing lung cancer, in order to further the discovery of preventive actions.
1. Kaderi MA, Norberg M, Murray F, Merup M, Sundström C, Roos G, et al. The Bcl-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia. Leukemia 2008;22:339-43.
2. Young RL, Korsmeyer SJ. A negative regulatory element in the Bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol 1993; 13:3686-97.
3. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 1995; 80:293-299.
4. Nückel H, Frey UH, Sellmann L, Bau M Dürig J, Dührsen U, et al. Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survival. Leukemia 2006; 20:724.
5. Chen K, Hu Z, Wang LE, Sturgis EM, El-Naggar AK, Zhang W, et al. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of Bax and Bcl-2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2007; 28:2008-12.
6. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124:1-6.
7. Rodríguez I, Coto E, Reguero JR, González P, Andrés V, Lozano I, et al. Role of the CDKN1A/p21, CDKN1C/p57 and CDKN2A/р16 genes in the risk of atherosclerosis and myocardial infarction. Cell Cycle 2007; 6:620-5.
8. Pasquali D, Circelli L, Faggiano A, Pancione M, Renzullo A, Elisei R, et al. CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. Eur J Endocrinol 2011; 164:397-404.
9. Ning Zhang, Xiaoyan Li, Kai Tao, Liyu Jiang, Tingting Ma, Shi Yan, et al. Bcl-2 (-938C>A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet 2011; 12:48. Published online 2011 April 1. doi: 10.1186/1471-2350-12-48.
10. Starczynski J, Pepper C, Pratt G, Hooper L, Thomas A, Milligan D, et al. Common polymorphism G(-248)A in the promoter region of the Bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. J Clin Oncol 2005; 23:1514-21.
11. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 2003; 63:2033-6.
12. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, 1973.
13. Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, et al. Regulatory Bcl-2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer 2011; 129:2390-9.
The fully formatted PDF version is available.
Int J Biomed. 2012;2(3):197-200.©2012 International Medical Research and Development Corporation. All rights reserved.